Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis

Janmaat, Vincent T.; Olphen, Sophie H. van; Biermann, Katharina; Looijenga, Leendert H. J.; Bruno, M.; Spaander, Manon

doi:10.1371/journal.pone.0186305

Cited by 29 publications

(17 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another showed aberrant expression of p53 protein as a representative biomarker for prediction of neoplastic progression in BE [ 84 , 85 , 86 , 87 , 88 ]. Moreover, the TP53 mutation was found in 46% of patients with EAC progression [ 25 ], and reported to be associated with EAC progression with an OR of 3.18 (95% CI 1.68–6.03) [ 24 ] and an HR of 6.5 (95% CI 2.5–17.1) [ 89 ].…”

Section: Endoscopic Findings Showing Possible Predictive Biomarkermentioning

confidence: 99%

“…In an investigation of aspergillus oryzae lectin (AOL) as a new biomarker, it was demonstrated that not only abnormal DNA ploidy but also AOL could be used to identify BE patients who were most likely to develop dysplastic Barrett’s lesions [ 92 , 94 ]. Janmaat VT et al also reported that AOL was a useful biomarker to predict neoplastic progression, with an OR of 3.04 (95% CI 2.05–4.49) [ 24 ].…”

Section: Endoscopic Findings Showing Possible Predictive Biomarkermentioning

confidence: 99%

“…Recently, biomarkers including epigenetics and miRNA analysis findings, DNA content abnormalities, and loss of heterozygosity noted in biopsy findings have been reported to be additional reliable predictors of malignant transformation in affected patients [ 23 ]. One of the most important biomarkers is aberrant expression and/or mutation of p53 [ 24 , 25 ]. Some of these biomarkers become to be detectable by specialized endoscopic devices such as autofluorescence endoscopy, optical coherence tomography, endocytoscopy, confocal endomicroscopy, or near-infrared imaging endoscopy, although use of these novel markers is difficult in clinical settings because of the complicated biochemical procedures required.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings?

Amano

Ishimura

Ishihara

2020

Life

View full text Add to dashboard Cite

Given that endoscopic findings can be used to predict the potential of neoplastic progression in Barrett’s esophagus (BE) cases, the detection rate of dysplastic Barrett’s lesions may become higher even in laborious endoscopic surveillance because a special attention is consequently paid. However, endoscopic findings for effective detection of the risk of neoplastic progression to esophageal adenocarcinoma (EAC) have not been confirmed, though some typical appearances are suggestive. In the present review, endoscopic findings that can be used predict malignant potential to EAC in BE cases are discussed. Conventional results obtained with white light endoscopy, such as length of BE, presence of esophagitis, ulceration, hiatal hernia, and nodularity, are used as indicators of a higher risk of neoplastic progression. However, there are controversies in some of those findings. Absence of palisade vessels may be also a new candidate predictor, as that reveals degree of intense inflammation and of cyclooxygenase-2 protein expression with accelerated cellular proliferation. Furthermore, an open type of mucosal pattern and enriched stromal blood vessels, which can be observed by image-enhanced endoscopy, including narrow band imaging, have been confirmed as factors useful for prediction of neoplastic progression of BE because they indicate more frequent cyclooxygenase-2 protein expression along with accelerated cellular proliferation. Should the malignant potential of BE be shown predictable by these endoscopic findings, that would simplify methods used for an effective surveillance, because patients requiring careful monitoring would be more easily identified. Development in the near future of a comprehensive scoring system for BE based on clinical factors, biomarkers and endoscopic predictors is required.

show abstract

Section: Endoscopic Findings Showing Possible Predictive Biomarkermentioning

confidence: 99%

Section: Endoscopic Findings Showing Possible Predictive Biomarkermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings?

Amano

Ishimura

Ishihara

2020

Life

View full text Add to dashboard Cite

show abstract

“…The detection of molecular alterations of the Barrett’s epithelium could be a useful tool for risk stratification and prediction of response to therapy. For example, p53 aberrant expression (either absent or overexpression) detected by immunohistochemistry has been extensively studied, and could be as discriminative as the presence of LGD in the prediction of neoplastic progression [ 92 , 93 ]. Furthermore, analysis of the p53 expression pattern could help in improving the diagnostic accuracy of esophageal biopsies and lowering the rate of “indefinite for dysplasia” [ 94 ].…”

Section: Perspectivesmentioning

confidence: 99%

Diagnosis and treatment of superficial esophageal cancer

Barret

Prat

2018

aog

View full text Add to dashboard Cite

Endoscopy allows for the screening, early diagnosis, treatment and follow up of superficial esophageal cancer. Endoscopic submucosal dissection has become the gold standard for the resection of superficial squamous cell neoplasia. Combinations of endoscopic mucosal resection and radiofrequency ablation are the mainstay of the management of Barrett’s associated neoplasia. However, protruded, non-lifting or large lesions may be better managed by endoscopic submucosal dissection. Novel ablation tools, such as argon plasma coagulation with submucosal lifting and cryoablation balloons, are being developed for the treatment of residual Barrett’s esophagus, since iatrogenic strictures still hamper the development of extensive circumferential resections in the esophagus. Optimal surveillance modalities after endoscopic resection are still to be determined. The assessment of the risk of lymph-node metastases, as well as of the need for additional treatments based on qualitative and quantitative histological criteria, balanced to the patient’s condition, requires a dedicated multidisciplinary team decision process. The need for trained endoscopists, expert pathologists and surgeons, and specialized multidisciplinary meetings underlines the role of expert centers in the management of superficial esophageal cancer.

show abstract

“…Extensive studies have been conducted to explore the potential ancillary biomarkers for the diagnosis of BE-related dysplasia. Among them, p53 expression is the most promising diagnostic and prognostic marker [61,62]. In one study, positive p53 expression was found in 0% of BE ND cases, 9% of LGD cases, 55% of HGD cases, and 87% of those with EAC [63].…”

Section: Ancillary Biomarkers For Be Dysplasia and Early Stage Eacmentioning

confidence: 99%

Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review

Yin

Gonzálo

Lai

et al. 2018

Gastrointestinal Disorders

View full text Add to dashboard Cite

Esophageal adenocarcinoma carries a very poor prognosis. For this reason, it is critical to have cost-effective surveillance and prevention strategies and early and accurate diagnosis, as well as evidence-based treatment guidelines. Barrett’s esophagus is the most important precursor lesion for esophageal adenocarcinoma, which follows a defined metaplasia–dysplasia–carcinoma sequence. Accurate recognition of dysplasia in Barrett’s esophagus is crucial due to its pivotal prognostic value. For early-stage esophageal adenocarcinoma, depth of submucosal invasion is a key prognostic factor. Our systematic review of all published data demonstrates a “rule of doubling” for the frequency of lymph node metastases: tumor invasion into each progressively deeper third of submucosal layer corresponds with a twofold increase in the risk of nodal metastases (9.9% in the superficial third of submucosa (sm1) group, 22.0% in the middle third of submucosa (sm2) group, and 40.7% in deep third of submucosa (sm3) group). Other important risk factors include lymphovascular invasion, tumor differentiation, and the recently reported tumor budding. In this review, we provide a concise update on the histopathological features, ancillary studies, molecular signatures, and surveillance/management guidelines along the natural history from Barrett’s esophagus to early stage invasive adenocarcinoma for practicing pathologists.

show abstract

Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis

Cited by 29 publications

References 54 publications

Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings?

Is Malignant Potential of Barrett’s Esophagus Predictable by Endoscopy Findings?

Diagnosis and treatment of superficial esophageal cancer

Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review

Contact Info

Product

Resources

About